Danaher (NYSE:DHR) Issues Earnings Results, Hits Expectations

Danaher (NYSE:DHR) announced its earnings results on Wednesday. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14, RTT News reports. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same period in the prior year, the business posted $2.09 earnings per share.

Danaher Price Performance

DHR opened at $230.22 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher has a 1-year low of $225.42 and a 1-year high of $281.70. The company has a 50-day moving average of $236.09 and a 200-day moving average of $253.66. The company has a market capitalization of $166.28 billion, a P/E ratio of 43.90, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

Several analysts have commented on the stock. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Guggenheim assumed coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, Citigroup reduced their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.81.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.